Scarica l'app Stockscreener
204.31
1.32%
-2.73
Dopo l'orario di chiusura:
204.30
-0.010
-0.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$207.04
Aprire:
$202.93
Volume 24 ore:
882.68K
Relative Volume:
0.90
Capitalizzazione di mercato:
$14.38B
Reddito:
$2.71B
Utile/perdita netta:
$247.10M
Rapporto P/E:
58.36
EPS:
3.5008
Flusso di cassa netto:
$349.90M
1 W Prestazione:
-6.33%
1M Prestazione:
-16.76%
6M Prestazione:
-34.56%
1 anno Prestazione:
-24.09%
Intervallo 1D:
$202.44
$209.35
Intervallo di 1 settimana:
$202.44
$218.04
Portata 52W:
$202.44
$354.88
Insulet Corporation Stock (PODD) Company Profile
Nome
Insulet Corporation
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
204.31 | 14.38B | 2.71B | 247.10M | 349.90M | 3.5008 |
ABT
Abbott Laboratories
|
102.87 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.54 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.63 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.82 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Ripresa | TD Cowen | Hold |
| 2026-01-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Iniziato | Evercore ISI | Outperform |
| 2025-11-19 | Aggiornamento | UBS | Neutral → Buy |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corporation Borsa (PODD) Ultime notizie
Insulet Corp. Stock Plummets to New 52-Week Low of $203.19 - Markets Mojo
Insulet Corporation (PODD) Stock forecasts - Yahoo Finance UK
Aberdeen Group plc Has $64.08 Million Stock Position in Insulet Corporation $PODD - MarketBeat
PODD PE Ratio & Valuation, Is PODD Overvalued - intellectia.ai
Insulet (PODD): 3 Reasons We Love This Stock - Yahoo Finance
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy? - finance.yahoo.com
Insulet Corp. Stock Hits 52-Week Low at USD 208.14 - Markets Mojo
Assessing Insulet (PODD) Valuation After Omnipod 5 Device Correction And Maintained Outlook - Sahm
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
Insulet Corp (PODD) EVP receives new stock options and RSU awards - Stock Titan
INSULET CORP (PODD) EVP and CCO Michael Panos reports 5-share stake - Stock Titan
Insulet (PODD) board member elects 111 deferred stock units as fees - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet CorporationPODD - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Insulet Corporation (PODD) And Encourages Shareholders to Connect - ACCESS Newswire
Insulet Corp (NASDAQ:PODD): A Prime GARP Investment with Strong Growth and Reasonable Valuation - ChartMill
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026 - BioSpace
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves - Sahm
Insulet Corp (1PODD.MI) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Insulet Corporation (PODD) Stock Forecasts - Yahoo Finance
Insulet Corporation Trade Ideas — MIL:1PODD - TradingView
PODD Investor Alert: Insulet Corp. Potential Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky - Morningstar
Does Insulet (PODD) Elevate Its Diabetes Tech Edge With Panos Steering Global Commercial Strategy? - Yahoo Finance
7,473 Shares in Insulet Corporation $PODD Acquired by J. Safra Sarasin Holding AG - MarketBeat
Truist maintains Insulet Corporation (PODD) buy rating despite device correction announcement - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insulet Corporation (PODD) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why (PODD) Price Action Is Critical for Tactical Trading - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet ... - Bluefield Daily Telegraph
Winners And Losers Of Q4: Insulet (NASDAQ:PODD) Vs The Rest Of The Patient Monitoring Stocks - Yahoo Finance
Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD - MarketBeat
Insulet (NASDAQ:PODD) Reaches New 12-Month LowTime to Sell? - MarketBeat
Insulet names Mike Panos as chief commercial officer By Investing.com - Investing.com South Africa
Insulet Earnings: Stellar Finish to 2025 With Strong Fourth Quarter - Morningstar
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insulet Corporation (PODD) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Insulet Corp. Stock Hits New 52-Week Low at USD 215.26 - Markets Mojo
Consumer safety roundup: Major recalls affect Einstein Bros., Insulet, Amneal and Falcon Trading - Washington Times
Insulet Corp (PODD) Shares Down 4.53% on Mar 30 - GuruFocus
Is Insulet’s (PODD) New CCO Hire a Subtle Reset of Its Global Commercial Strategy? - simplywall.st
Insulet Corporation Appoints Mike Panos as Executive Vice President and Chief Commercial Officer, Effective March 30, 2026 - MarketScreener
Insulet names Mike Panos as chief commercial officer - Investing.com
Insulet Appoints Mike Panos as Chief Commercial Officer - Bakersfield.com
Truist Maintains Insulet Corporation (PODD) Buy Rating Despite Device Correction Announcement - Insider Monkey
SG Americas Securities LLC Purchases 36,570 Shares of Insulet Corporation $PODD - MarketBeat
Beacon Investment Advisory Services Inc. Cuts Position in Insulet Corporation $PODD - MarketBeat
Insulet Corporation (PODD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Insulet recalling certain defective Omnipod insulin delivery devices - MSN
PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm - Business Wire
Is Insulet stock underperforming the Dow? - MSN
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know - Yahoo Finance
2026-03-27 | Insulet Corporation (PODD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:PODD | Press Release - Stockhouse
Insulet Corporation Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):